Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Yokota T, Ogawa T, Takahashi S, Okami K, Fujii T, Tanaka K, Iwae S, Ota I, Ueda T, Monden N, Matsuura K, Kojima H, Ueda S, Sasaki K, Fujimoto Y, Hasegawa Y, Beppu T, Nishimori H, Hirano S, Naka Y, Matsushima Y, Fujii M, Tahara M. Yokota T, et al. Among authors: fujii m, fujii t. BMC Cancer. 2017 May 5;17(1):314. doi: 10.1186/s12885-017-3295-4. BMC Cancer. 2017. PMID: 28476132 Free PMC article. Clinical Trial.
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T, Tsuboi K, Ohashi N, Fujii T, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y. Nakayama G, et al. Among authors: fujii t. Cancer Chemother Pharmacol. 2012 Oct;70(4):575-81. doi: 10.1007/s00280-012-1948-1. Epub 2012 Aug 12. Cancer Chemother Pharmacol. 2012. PMID: 22886005 Free PMC article. Clinical Trial.
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Nakayama G, Tanaka C, Uehara K, Mashita N, Hayashi N, Kobayashi D, Kanda M, Yamada S, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Ando Y, Kodera Y. Nakayama G, et al. Among authors: fujii t. Cancer Chemother Pharmacol. 2014 Apr;73(4):847-55. doi: 10.1007/s00280-014-2416-x. Epub 2014 Feb 28. Cancer Chemother Pharmacol. 2014. PMID: 24577566 Clinical Trial.
Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial.
Okada K, Kawai M, Hirono S, Fujii T, Kodera Y, Sho M, Nakajima Y, Satoi S, Kwon AH, Shimizu Y, Ambo Y, Kondo N, Murakami Y, Ohuchida J, Eguchi H, Nagano H, Oba MS, Morita S, Sakamoto J, Yamaue H; JAPAN-PD Investigators. Okada K, et al. Among authors: fujii t. Surgery. 2016 May;159(5):1333-41. doi: 10.1016/j.surg.2015.11.019. Epub 2015 Dec 31. Surgery. 2016. PMID: 26747224 Free article. Clinical Trial.
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. Nakayama G, et al. Among authors: fujii t. BMC Cancer. 2017 Apr 4;17(1):243. doi: 10.1186/s12885-017-3245-1. BMC Cancer. 2017. PMID: 28376737 Free PMC article. Clinical Trial.
6,521 results